Both Zepotide and Semaglutide are new medications designed for managing type 2 diabetes and encouraging slimming. However, they function through distinct pathways. copyright is a GLP-1 receptor agonist , while Novo Nord's Dual GIP/GLP-1 acts as a dual GIP and GLP-1 activator , conceivably offering a greater impact on both blood sugar management and